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Abstract
Background: The aim of this study was to develop and optimize deformable liposome for topical delivery of
tretinoin.
Methods: Liposomal formulations were designed based on the full factorial design and prepared by fusion
method. The influence of different ratio of soy phosphatidylcholine and transcutol (independent variables) on
incorporation efficiency and drug release in 15 min and 24 h (responses) from liposomal formulations was
evaluated. Liposomes were characterized for their vesicle size and Differential Scanning Calorimetry (DSC) was used
to investigate changes in their thermal behavior. The penetration and retention of drug was determined using
mouse skin. Also skin histology study was performed.
Results: Particle size of all formulations was smaller than 20 nm. Incorporation efficiency of liposomes was 79–93 %.
Formulation F7 (25:5) showed maximum drug release. Optimum formulations were selected based on the contour
plots resulted by statistical equations of drug release in 15 min and 24 h. Solubility properties of transcutol led to
higher skin penetration for optimum formulations compared to tretinoin cream. There was no significant difference
between the amount of drug retained in the skin by applying optimum formulations and cream. Histopatological
investigation suggested optimum formulations could decrease the adverse effect of tretinoin in liposome
compared to conventional cream.
Conclusion: According to the results of the study, it is concluded that deformable liposome containing transcutol
may be successfully used for dermal delivery of tretinoin.
Keywords: Statistical optimization, Tretinoin, Liposomal formulation, Topical delivery
Background
Tretinoin or all-trans retinoic acid in topical form is
commonly used for the treatment of various skin prob-
lems like acne, photoaging and psoriasis. Furthermore, it
has other functions such as sebum production, collagen
synthesis and regulating growth and differentiation of
epithelial cells [1]. Reduction the size and the number of
comedones are considered to be the main effect of tre-
tinoin in the treatment of acne [2]. However, it has sev-
eral negative points even in topical use such as very low
water solubility, skin irritation and high instability in the
presence of air, light and heat. Furthermore, local irrita-
tion such as erythema, peeling and burning at the appli-
cation site and increased susceptibility to sunlight are its
side effects [3].
Liposomes are spherical-shaped carriers which has an
internal aqueous portion surrounded by one or multiple
concentric lipidic bilayers. Liposomes are used as car-
riers for both lipophilic and water soluble molecules.
Hydrophilic substances are encapsulated in the interior
aqueous portions whereas lipophilic substances are en-
trapped within lipid bilayers [4].
Incorporation of tretinoin in nanostructure systems
such as liposomes may lead to decrease the adverse effects
and protect this molecule against degradation [5–8].
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Liposomes were first used as topical therapy by Mezei
and Gulasekharam in 1980. The introduction of lipo-
somes as skin drug delivery systems, initially promoted
for localized effects with minimal systemic delivery. Re-
duction of vesicle size improves drug deposition into
deeper strata. Recent advances and alteration in the
composition and structure of vesicles result in vesicles
with tailored properties [9].
The first generations of elastic vesicles are deform-
able liposomes (Transfersomes®) which consist of
phospholipids and surfactant as an edge activator.
Surfactant destabilizes lipid bilayers and increases
deformability of the vesicles. Ethosome is another
type of elastic vesicle which is composed of phospho-
lipid, ethanol and water [10]. Recently, a novel family
of liposomes which named the Penetration Enhancer-
containing Vesicles (PEVs) is described for enhanced
(trans)-dermal drug delivery [11]. They mainly consist
of phospholipids and penetration enhancers with
hydrosoluble glycols such as diethylene glycol mono
ethyl ether or propylene glycol. Transient reduction
of the stratum corneum barrier function and im-
provement in vesicular bilayer fluidity are two main
functions of the PEVs [12].
The aim of this study was to prepare and evaluate de-
formable liposome using soy phosphatidylcholine and
transcutol (Diethylene glycol monoethyl ether) for top-
ical delivery of tretinoin. Also optimization of formula-
tion was performed in order to obtain suitable dermal
delivery system for tretinoin.
Methods
Materials
Tretinoin was purchased from Sepidaj (Iran). Soy
phosphatidylcholine (phospholipon 85G®) was ob-
tained from lipoid (Germany). Cholesterol and HEPES
(4-(2-Hydroxyethyl) 1-piperazine ethanesulfonic acid)
were purchased from Sigma)Germany). Diethylene
glycol monoethyle ether (Transcutol®) received as a
gift from Gattefosse (France). Propyl paraben, methyl
paraben, propylene glycol and vitamin E were ob-
tained from Merck (Germany). Tretinoin cream
0.05 % was purchased from the pharmacy and its
base cream was provided as a gift by Iran Daru
(Iran).
Animals
Female NMRI mice 7–9 weeks old were obtained from
laboratory Animals Care and Breeding Center of Ahvaz
Jundishapur University of Medical Sciences (Ahvaz,
Iran). The experiments were conducted in full compli-
ance with regulatory principles of ethics committee of
Ahvaz Jundishapur University of Medical Sciences.
Experimental design
A full factorial 32 design was used for optimization
procedure. The studied independent variables were
amount of soy phosphatidylcholine (SPC) (X1) and
amount of transcutol (X2) in formulation. Types and
levels of the independent variables are listed in
Table 1. Dependent variables (responses) were percent
of incorporation efficiency (Y1), percent of drug re-
lease in 15 min (Y2) and percent of drug release in
24 h (Y3). The resulted formulations are illustrated in
Table 2.
Preparation of deformable liposomes
Deformable liposomes were prepared by the fusion
method. Briefly, the lipid components consisted of
SPC (15–20–25 % wt), transcutol (5–10–15 % wt),
tretinoin) 0.05 % wt), cholesterol (2 % wt), propylene
glycol (3 % wt), vitamin E (0.3 % wt), metyl paraben
(0.1 % wt), and propyl paraben (0.02 % wt); these
components were melted at about 75 °C. HEPES buf-
fer (10 mM, pH 5) was heated separately and was
added up to 100 % to the previously heated melted
lipids, and the mixture was homogenized with a
homogenizer (Ultra-Turrax IKA T25) for 5 min at
12,000 rpm and allow it to cool down to room
temperature [13].
Characterization of the liposomes
Particle size measurement
The particle size of the samples were measured in tripli-
cate by laser light scattering (Scatterscope 1, Qudix,
South Korea). Samples were diluted in HEPES buffer to
a suitable concentration (0.2 g formulation in 1 ml
HEPES buffer).
Incorporation efficiency
Incorporation efficiency of liposomes was determined
indirectly. Certain amounts of liposomal dispersions
were centrifuged (VS-35SMTI, Korea) at 20,000 rpm
for 25 min at 25 °C. The supernatant was collected
and analyzed at 362 nm using UV spectrophotometer
(Biowave II, Biochrom, England) [14]. The percent of
incorporation efficiency of drug was calculated by the
following formula:
Table 1 Independent variables: Types and Levels
Variables Levels
X1: amount of SPC (% wt) 15 20 25
X2: amount of transcutol (% wt) 5 10 15
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EE% ¼

amount of initial drug
– amount of free drug in supernatant

=amount of initial drug

 100
In vitro drug release
Drug release studies were performed using dialysis
membrane method. Dialysis membranes were soaked be-
fore use in distilled water for 20 h. 1 g of formulation
was placed in a dialysis membrane and both ends were
closed. The membrane was float in a beaker containing
150 ml phosphate buffer (pH 7.4) and methanol (2:1 v/
v); and stirred at 200 rpm at 37 °C. 1 ml of receiver
medium was removed at 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8
and 24 h and same volume of the fresh medium was re-
placed. The collected samples were analyzed for their
tretinoin content. The derived concentration values were
corrected by using the equation (1):
Mt nð Þ ¼ Vr Cnþ Vs
X
Cm ð1Þ
Where Mt(n) is the current cumulative mass of
drug transported across the membrane at time t, n is
the number (times) of sampling, Cn is the current
concentration in the receiver medium, ∑Cm is the
summed total of the previously measured concentra-
tions, Vr is the volume of the receiver medium, and
Vs corresponds to the volume of the sample removed
for analysis [15, 16].
Viscosity
Viscosity of selected formulations were measured by
Brookfield viscometer (DV II + Pro, US) at 10 rpm and
25 °C using spindle 64.
In vitro skin penetration and retention
In vitro skin penetration studies were performed using
jacketed Franz cells with a receiver medium of 25 ml
Phosphate buffer (pH 7.4) and methanol (2:1 v/v) at 37 °C
and surface area of 4.84 cm2. The dorsal skin of mouse
was shaved with electric clippers one day before the ex-
periment. A suitable size of full-thickness skin of mouse
was cut and clamped between the donor and receiver
compartment of Franz cell with the stratum corneum side
facing upward. The skin samples were initially left in the
Franz cells for 30 min in order to facilitate hydration. Sub-
sequently, 1 g of the optimum formulations and tretinoin
cream were placed onto the skin surface. 1 ml of receiver
solution was removed at 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6 and
8 h and same volume of the fresh medium was replaced.
The collected samples were analyzed for their tretinoin
content. The derived concentration values were corrected
according to equation (1).
For the determination of the amount of the drug
retained in the skin, at the end of the experiment, the
amount of the formulation remaining on the surface of
the skin was collected and assayed for tretinoin. The
amount of tretinoin retained in the skin was then calcu-
lated by subtracting the sum of the amount of tretinoin
that remained on the surface and the amount of tretin-
oin that was released (penetrated through the skin) from
the whole applied amount [13].
The cumulative amount of drug permeated was plot-
ted against time. The steady-state permeation rate (Jss)
was calculated by divided the slop of the linear portion
of the plot on the exposed surface area of the skin. Lag
time was determined from the x-intercept of the linear
portion of the plot [17].
Histological evaluation
For skin histological study the dorsal side of the mouse
was shaved with electric clipper. The skin was cut and
mounted between donor and receiver compartment of
the jacketed Franz cell whit stratum corneum side facing
upward. 1 g of optimum formulations and tretinoin
cream were placed on the skin. After 38 h the excessive
formulation and cream were removed and the skin
cleaned with cotton soaked in a phosphate buffer solu-
tion (pH 7.4). The treated skins were fixed in 10 % for-
malin solution and embedded in paraffin wax. Then
samples were cut in 5 μm thick sections by using micro-
tome and conventionally stained with haematoxylin and
eosin (H&E). Finally the samples were examined by light
microscope (Olympus, BH-2, Japan) [18].
Differential scanning calorimetry (DSC)
DSC thermograms of SPC, cholesterol, transcutol and
tretinoin were recorded on a differential scanning calor-
imeter (Mettler Toledo, DSC-1, Switzerland). Thermo-
grams of both blank and tretinoin loaded liposomes
were recorded individually. Certain amount of sample
Table 2 Composition of experimental formulations (runs)
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was placed in aluminum pan and scanned from 20 to
200 °C by scanning rate of 10 °C/min.
Stability study
Optimum formulations were stored at refrigerate
temperature (4 °C) for 3 months. After 1 and3 months,
the particle size and drug incorporation efficiency of the
formulations were measured. The results were compared
with the initial size and drug incorporation efficiency of
formulations [19].
Statistical analysis
All experiments were repeated three times and
expressed as the mean ± standard deviation. One way
analysis of variance (ANOVA) followed by multiple
comparisons Tukey test was used to substantiate statis-
tical differences between groups. Results with P < 0.05
were considered to be significant.
The effects of independent variables (X) on the
dependent variables (Y) were modeled using a polyno-
mial second order equation as followed:
Y ¼ c þ b1X1 þ b2X2 þ b3X12 þ b4X22
þ b5X1X2
The modeling was performed using SPSS (Version
16.0) with a backward, stepwise linear regression tech-
nique and significant expressions (P < 0.05) were selected
for the final equations. Response surface plots and con-
tour plots resulting from equations obtained by Stat-
graphics version Centurion XVI.
Results and discussion
In an attempt to obtain suitable formulation containing
tretinoin for dermal delivery, deformable liposomes pre-
pared with SPC and transcutol.
Transcutol (diethylene glycol monoethylether) is a
non-toxic, biocompatible with skin, penetration enhan-
cer which is miscible in polar and non polar solvents
[20]. Effect of transcutol on the lipid organizational
structure of human stratum corneum was evaluated by
Moghadam et al. [21]. Their results of x-ray scattering
study showed transcutol caused a slight disordering ef-
fect in the stratum corneum membrane and increasing
its fluidity.
In this study the fusion method was used to prepare
the topical liposomal formulations. This method is sim-
ple, efficient, and reproducible. The method is free of or-
ganic solvents like chloroform; and yields homogeneous
liposomes with high incorporation efficiencies. Further-
more, liposomes prepared by fusion method showed
enough viscosity that they could be applied directly on
the skin without the need for the liposomal formulation
to be mixed with other bases [9].
Characterization of the liposomes
Particle size
The mean particle size of the liposomal formulations was
shown in Table 3. ANOVA analysis showed statistical sig-
nificant differences between F2 and F1, F8, F9 (P < 0.05)
and also, F4 and F9 (P < 0.05). Different concentrations of
phospholipid and transcutol showed no effect on particle
size of liposomal formulations.
Incorporation efficiency
The incorporation efficiency of formulations was in
range of 79 to 93 % (Table 3). F8 showed maximum
Table 3 Particle size (nm) and Incorporation efficiency (%) of
liposomal formulations (mean ± SD, n = 3)
Formulation Average size Incorporation (%)
1 8.82 ± 0.95 85.51 ± 0.15
2 16.96 ± 3.69 80.88 ± 0.19
3 10.94 ± 1.84 79.11 ± 0.19
4 15.09 ± 4.62 89.55 ± 0.19
5 9.59 ± 2.99 91.33 ± 0.57
6 12.8 ± 1.65 89.88 ± 0.19
7 10.21 ± 1.85 93.22 ± 0.69
8 7.70 ± 2.30 93.88 ± 0.19
9 7.12 ± 0.74 89.99 ± 0.33
Fig. 1 Response surface plot for Y1 response (percent of incorporation efficiency)
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percent of incorporation. There were no statistical sig-
nificant differences among F4, F6, F9 (P > 0.05) and also,
between F7 and F8 (P > 0.05).
Mathematical relationships were generated between
the responses and independent variables using the
statistical package SPSS. The equations of the re-
sponses represent the quantitative effect of independ-
ent variables (X1 and X2) upon the responses (Y1, Y2
and Y3). Coefficients with more than one factor rep-
resent the interaction between factors while coeffi-
cients with second order terms indicate the quadratic
nature of the phenomena.
The equation of the Y1 (percent of incorporation effi-
ciency) is given below:
Y1 ¼ 20:560
þ 6:101 X1– 0:126 X12– 0:016 X22 ð2Þ
Three-dimensional response surface plot for Y1 is
shown in Fig. 1. According to the Fig. 1, incorporation
efficiency was increased by increasing the amount of
phospholipid, while it was slightly decreased with higher
amounts of transcutol. The lipophilic nature of tretinoin
may lead to incorporation of this drug between the lipid
Fig. 2 Release profiles of tretinoin from various liposomal formulations and tretinoin cream
Table 4 Analysis of variance (ANOVA) of dependent variables (percent of incorporation efficiency (Y1) and percent of drug release in
15 min (Y2) and 24 h (Y3))
Source of variation Sum of squares Degree of freedom Mean square F ratio P-value
Y1
Regression 604.968 3 201.656 87.409 0.000




Regression 716.867 4 179.217 23.780 0.000




Regression 1569.312 4 392.328 87.047 0.000
Residuals 99.156 22 4.507
Total 1668.468 26
R2 = 0.941
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bilayers. This can also explain the high incorporation ef-
ficiency of the tretinoin in liposomal formulations [22].
In vitro drug release
The release profile of tretinoin from various liposomal
formulations and conventional tretinoin cream are
shown in Fig. 2. In the first 2 h, drug release from F8
and F9 were significantly (P < 0.05) higher than other
formulations, at the 4th hour no statistical significant dif-
ferences were observed among F7, F8 and F9 (P > 0.05)
and after 8 and 24 h, F7 showed maximum drug release
compared with other formulations. The release pattern
of tretinoin cream and all liposomal formulations except
F7, showed burst release in initial times and then had a
reduced rate of release [23].
The target of optimization was to obtain formulations
with slow release in first 15 min and maximum release
at 24 h. Therefore constraints for the Y2 (percent of drug
release in 15 min) and Y3 (percent of drug release in
24 h) were:
Y2 < 15 % and Y3 > 30 %
The equations of the responses Y2 and Y3 are given
below:
Y2 ¼ 101:07 – 9:207 X1– 1:666 X2
þ 0:111 X1X2 þ 0:223 X12 ð3Þ
Y3 ¼ 149:821 – 14:491 X1– 0:177 X1X2
þ 0:431 X12 þ 0:194 X22 ð4Þ
Analysis of variance (ANOVA) (Table 4) demonstrated
that the mathematical models generated were statisti-
cally significant and valid for each considered response.
Three-dimensional response surface plot for Y2 and Y3
are shown in Figs. 3 and 4. As shown in Fig. 3, drug re-
lease was decreased in 15 min by increase in the concen-
trations of phospholipids up to 20 %. Meanwhile,
increase in the amount of phospholipid from 20 to 25 %,
higher the value of drug release. Also it was shown that
formulations with higher amounts of transcutol in their
compositions released more elements of drug at 15 min.
According to Fig. 4, liposomes containing about 17–
19 % phospholipid exhibited the lowest drug release
among the formulations. However, it was increased by
either lower or higher phospholipid concentrations so
that drug release at 24 h from formulations composed of
25 % phospholipid (F7, F8 and F9) was maximums.
The phase transition temperature (Tm) of the lipids af-
fected the release of liposome [24]. Phospholipids at
their Tm changed from solid to liquid state. Thus the
Fig. 3 Response surface plot for Y2 Response (percent of drug release in 15 min)
Fig. 4 Response surface plot for Y3 Response (percent of drug release in 24 h)
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permeability of liposomal membrane is increased and
encapsulated drug released [25]. Chen et al. [26] pre-
pared stealth liposome with different phosphatidylcho-
line and found liposome composed SPC in the presence
of rat plasma showed maximum drug release which due
to lower Tm of SPC.
According to contour plots of responses Y2 and Y3
(Fig. 5), optimized formulations were selected. The de-
fined desirable areas of responses Y2 and Y3 were super-
imposed and the region of interest was found. The ratio
of SPC: transcutol to obtained optimum formulations
were 15.5:14.5, 24:7 and 25:5.
As a validation method for the process, liposomal for-
mulations were prepared at the predicted levels of the
independent variables and evaluated for percent of drug
release in 15 min and 24 h. Observed and predicted re-
sponses for optimum formulations were then compared
and the results were shown in Table 5.
Viscosity of F (25:5) and F (15.5:14.5) were 354.53 ±
4.51 and 266.94 ± 3.17 poise, respectively. Formulation
(25:5) with the highest amount of phospholipid and low-
est amount of transcutol had more viscosity compared
with F (15.5:14.5). Thus Formulation (25:5) showed
slower release in initial times. Fetih et al. [27] developed
and evaluated liposomal gels of celecoxib and concluded
that inverse relationship presented between viscosity of
liposomal gels with drug diffusion rate and percent of
drug released.
According to the results presented in Table 5, ob-
served responses were close to predicted ones which
confirmed that the factorial design was valid for predict-
ing the optimum formulation.
In vitro skin penetration and retention
The skin penetration profile of F (15.5:14.5), F (24:7), F
(25:5) and conventional tretinoin cream are shown in
Fig. 5 Contour plots for Y2 Response (percent of drug release in 15 min) a and Y3 (percent of drug release in 24 h) b
Table 5 Observed and predicted responses (percent of drug release in 15 min (Y2) and 24 h (Y3)) for optimum formulations
Formulation (SPC: transcutol) Dependent variables Observed response Predicted response Residual
F (15.5:14.5) Y2 14.88 12.72 2.61
Y3 30.41 29.76 0.65
F (24:7) Y2 14.88 15.53 −0.65
Y3 33.28 30.06 3.22
F (25:5) Y2 12.97 15.81 - 2.84
Y3 38.43 39.64 - 1.21
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Fig. 6. The penetration percent of optimum formulations
was higher (P < 0.05) than tretinoin cream. F (15.5:14.5)
showed maximum percent of penetration.
According to the Table 6, F (15.5:14.5) showed max-
imum flux. Formulations and cream penetrated through
the skin without any lag time. The flux of F (15.5:14.5)
and F (24:7) were higher than cream (P < 0.05), while no
statistical significant differences found between F (25:5)
and tretinoin cream (P > 0.05).
ANOVA analysis showed statistical significant differ-
ences between Jss of optimum Formulations (P < 0.05).
These results showed that by enhancement of transcutol
concentration in the optimum formulations, percent of
penetration and flux was increased which can be due to
solubilizing properties of transcutol [28].
The percent of retained tretinoin and ratio of
retained drug in the skin to penetrated drug for
optimum formulations and tretinoin cream calculated
and results showed in Table 6. There was no signifi-
cant difference in the percent of retained tretinoin be-
tween optimum formulations and tretinoin cream
(P > 0.05). ANOVA analysis showed that no significant
difference among ratio of retention/penetration of
optimum formulations (P > 0.05) but tretinoin cream
showed higher ratio of retention/penetration than
F(15.5:14.5) and F(24:7) (P < 0.05) that could be attrib-
uted to higher flux in formulations containing higher
amount of transcutol.
Manconi et al. [29] evaluated PEVs with different
penetration enhancers for dermal delivery of tretinoin.
Their results showed PEVs improved cutaneous drug ac-
cumulation compared to control liposome. However,
PEVs containing transcutol and labrasol had lower drug
accumulated/drug permeated ratio because these vesi-
cles increased both tretinoin deposition and flux.
Mura et al. [30] prepared PEVs with labrasol, transcu-
tol and cineole for (trans) dermal delivery of minoxidil.
They concluded that PEVs improved drug deposition
into the skin when compared to the classic liposomes.
Caddeo et al. [31] developed PEVs with transcutol or
propylene glycol, liposomes and ethosomes for delivered
the diclofenac to the skin. Results showed PEVs contain-
ing transcutol led to higher drug accumulation in the skin
compared to other carriers, diclofenac solution and volta-
ren. Also they found PEVs containing transcutol perme-
ated the drug more than other vesicular formulations.
Histological evaluation
Histopathological investigation revealed that the thick-
ness of epidermis in skin samples treated with F
(15.5:14.5) (Fig. 7b) and F (25:5) (Fig. 7c) was same as
untreated skin (control group) (Fig. 7a) and hyperkera-
tosis was increased in comparison with control group. In
tretinoin cream treated skin, proliferations of keratino-
cytes were obvious and also hyperkeratosis was evident
(Fig. 7d). Similar results obtained by Ascenso et al. [32].
Fig. 6 In vitro permeation profiles of tretinoin from cream and optimum formulations through mice skin
Table 6 Permeation parameters, Retention (%) and ratio of retention/penetration of tretinoin from optimum formulations and
cream (mean ± SD, n = 3)
Formulation Jss (μg/cm2.h) Tlag (h) Retention (%) Retention/Penetration
F(15.5:14.5) 4.71 ± 1 0 12.97 ± 2 0.72 ± 0.1
F(24:7) 3.29 ± 0.08 0 8.27 ± 1.91 0.63 ± 0.15
F(25:5) 1.05 ± 0.25 0 13.19 ± 0.71 1.18 ± 0.07
Tretinoin cream 0.88 ± 0.04 0 13.15 ± 2.77 1.72 ± 0.44
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They evaluated in vivo skin irritation potential of tretin-
oin loaded ultradeformable vesicles in comparison to
ketrel® and demonstrated ultradeformable vesicles
caused lowest skin irritation. Their histological study
showed in the skin treated with tretinoin loaded ultrade-
formable vesicle, hyperkeratosis was occurred and for
ketrel® treated skin hyperplasia was observed.
Raza et al. [1] developed lipid-based nanocariers for
dermal delivery of tretinoin and concluded these carriers
were well-tolerated on mouse skin while in the skin
treated with marketed product inflammation was
observed.
Castro et al. [33] prepared retinoic acid loaded solid
lipid nanoparticles and found this cariers considerably
reduced skin irritation in rabbit and rhino mouse models
when compared to marketed cream. Furthermore their
histological evaluation showed in skin treated with retin-
oic acid loaded solid lipid nanoparticles and marketed
gel epidermal thickness was increased in comparison to
placebo group.
Fig. 7 Photomicrographs (20×) of hairless mice skin sections after haematoxylin and eosin staining: a untreated skin, b skin treated with
F(15.5:14.5), c skin treated with F(25:5) and d skin treated with tretinoin cream 0.05 %
Fig. 8 DSC thermograms of A Blank F(15.5:14.5), B F(15.5:14.5), C Blank F(25:5), D F(25:5), E Tretinoin, F Transcutol, G Soy phosphatidylcholine,
H Cholesterol
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DSC
According to Fig. 8, DSC thermogram of tretinoin and
cholesterol showed endothermic peak at 170 °C and 140 °C
corresponding to their melting points, respectively [34, 35].
Transcutol thermogram showed endothermic peak about
195 °C, indicating its boiling point [36]. SPC thermogram
showed a broad peak at 88 °C. In case of tretinoin loaded li-
posomes, the melting point of tretinoin was not observed
which indicates that it is encapsulated in the liposome. The
blank and tretinoin loaded liposome showed peak around
100–120 °C in their thermograms, which may be caused by
evaporation of bounded water.
Stability study
The results of stability study for optimum formulations
are shown in Figs. 9 and 10. Over the course of
3 months, the mean particle size of formulations did not
change significantly (P > 0.05). This matter could be
resulted by the presence of transcutol in the formulation
that may cause flexibility in vesicles [30] and cholesterol
that has stabilizing effect against aggregation and fusion
of the liposomes [37]. Similar results obtained by Mura
et al. [38] that found particle size of PEVs with different
amounts of transcutol remained constant during
3 months at 4 °C. While, particle size of liposomes with-
out transcutol increased significantly. Incorporation effi-
ciency of F (24:7) and F (25:5) were significantly
decreased (P < 0.05) after 1 and 3 months while drug
loading of F (15.5:14.5) only decreased about 6 % after
3 months (P < 0.05).
Chessa et al. [39] evaluated influence of PEVs with dif-
ferent types of penetration enhancer on (trans) dermal
delivery of quercetin and concluded all PEVs promoted
drug deposition in the skin.
Srisuk et al. [40] prepared deformable liposomes
containing oleic acid for transepidermal delivery of
Fig. 9 Mean particle size (nm) of optimum formulations after 1 and 3 months storage at 4 °C
Fig. 10 Incorporation efficiency (%) of optimum formulations after 1 and 3 months storage at 4 °C
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methotrexate. These vesicles showed the highest skin
permeation, accumulation and flux compared to lipo-
somes without oleic acid and methotrexate solution.
Charoenputtakun et al. [41] developed solid lipid
nanoparticles, nanostructured lipid carriers and nanoe-
mulsions containing limonene or cineol as penetration
enhancer for dermal delivery of all-trans retinoic acid.
They demonstrated solid lipid nanoparticles containing
limonene had the highest skin permeation and flux in
compression to other formulations and all-trans retinoic
acid suspension.
Conclusion
PEVs are novel class of liposomes which consist of
phospholipid and penetration enhancer. In this work de-
formable liposome containing SPC and transcutol was
employed for dermal delivery of tretinoin. Particle size
of all formulations was smaller than 20 nm. Liposomes
showed high incorporation efficiency which may be due
to lipophilic nature of tretinoin. Formulations containing
25 % phospholipid exhibited the highest drug release at
24 h while the amount of transcutol did not significantly
change drug release. Drug penetrated through the skin
for optimum formulations was higher than cream which
can be due to solubilizing properties of transcutol.
Optimum formulations compared to tretinoin cream
caused milder hyperkeratosis without hyperplasia. These
results suggested that deformable liposomes could grad-
ually released tretinoin and thus decreased its adverse
effects such as erythema, peeling, burning and also in-
creased patient compliance.
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